Loading publications…
The last 5 uploaded publications
Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer
Mohsen Malehmir, Dominik Pfister, Suchira Gallage, Marta Szydlowska, Donato Inverso, Elena Kotsiliti, Valentina Leone, Moritz Peiseler, Bas G. J. Surewaard, Dominik Rath, Adnan Ali, Monika Wolf, Hannah K. Drescher, Marc E. Healy, Daniel Dauch, Daniela C. Kroy, Oliver Krenkel, Marlene Kohlhepp, Thomas Engleitner, Alexander Olkus, Tjeerd Sijmonsma, Julia Volz, Carsten Deppermann, David Stegner, Patrick M. Helbling, César Nombela‐Arrieta, Anahita Rafiei, Martina Hinterleitner, Marcel Rall, Florian Baku, Oliver Borst, Caroline Wilson, Jack Leslie, Tracy O’Connor, Chris J. Weston, Abhishek Chauhan, David H. Adams, Lozan Sheriff, Ana Teijeiro, Marco Prinz, Ruzhica Bogeska, Natasha S. Anstee, Malte N. Bongers, Mike Notohamiprodjo, Tobias Geisler, Dominic J. Withers, Jerry Ware, Derek A. Mann, Hellmut G. Augustin, Alexandros Vegiopoulos, Michael D. Milsom, Adam J. Rose, Patricia F. Lalor, Josep M. Llovet, Roser Pinyol, Frank Tacke, Roland Rad, Matthias S. Matter, Nabil Djouder, Paul Kubes, Percy A. Knolle, Kristian Unger, Lars Zender, Bernhard Nieswandt, Meinrad Gawaz, Achim Weber, Mathias Heikenwälder (2019). Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer. Nature Medicine, 25(4), pp. 641-655, DOI: 10.1038/s41591-019-0379-5.
Article145 days agoImmunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma
Laura Torrens, Carla Montironi, Marc Puigvehí, Agavni Mesropian, Jack Leslie, Philipp K. Haber, Miho Maeda, Ugne Balaseviciute, Catherine E. Willoughby, Jordi Abril‐Fornaguera, Marta Piqué‐Gili, Miguel Torres‐Martín, Judit Peix, Daniel Geh, Erik Ramón-Gil, Behnam Saberi, Scott L. Friedman, Derek A. Mann, Daniela Sia, Josep M. Llovet (2021). Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma. Hepatology, 74(5), pp. 2652-2669, DOI: 10.1002/hep.32023.
Article145 days agoCXCR2 inhibition enables NASH-HCC immunotherapy
Jack Leslie, John B. G. Mackey, Thomas Jamieson, Erik Ramón-Gil, Thomas M. Drake, Frédéric Fercoq, William Clark, Kathryn Gilroy, Ann Hedley, Colin Nixon, Saimir Luli, Maja Laszczewska, Roser Pinyol, Roger Esteban-Fabró, Catherine E. Willoughby, Philipp K. Haber, Carmen Andreu-Oller, Mohammad Rahbari, Chaofan Fan, Dominik Pfister, Shreya Raman, Niall Wilson, Miryam Müller, Amy Collins, Daniel Geh, Andrew Fuller, David McDonald, Gillian Hulme, Andrew Filby, Xabier Cortés-Lavaud, Noha-Ehssan Mohamed, Catriona A. Ford, Ximena L. Raffo Iraolagoitia, Amanda J. McFarlane, Misti McCain, Rachel A. Ridgway, Edward W. Roberts, Simon T. Barry, Gerard J. Graham, Mathias Heikenwälder, Helen L. Reeves, Josep M. Llovet, Leo M. Carlin, Thomas G. Bird, Owen J. Sansom, Derek A. Mann (2022). CXCR2 inhibition enables NASH-HCC immunotherapy. Gut, 71(10), pp. 2093-2106, DOI: 10.1136/gutjnl-2021-326259.
Article145 days agoHuman-correlated genetic models identify precision therapy for liver cancer
Miryam Müller, Stephanie May, H. G. HALL, Timothy J. Kendall, Lynn McGarry, Lauriane Blukacz, Sandro Nuciforo, Αναστασία Γεωργακοπούλου, Thomas Jamieson, Narisa Phinichkusolchit, Sandeep Dhayade, Toshiyasu Suzuki, Júlia Huguet‐Pradell, Ian R. Powley, Leah Officer-Jones, Rachel Pennie, Roger Esteban-Fabró, Albert Gris‐Oliver, Roser Pinyol, George Skalka, Jack Leslie, Matthew Hoare, Joep Sprangers, Gaurav Malviya, Agata Mackintosh, Emma Johnson, Misti McCain, John Halpin, Christos Kiourtis, Colin Nixon, Graeme M. Clark, William R. Clark, Robin Shaw, Ann Hedley, Thomas M. Drake, Ee Hong Tan, Matt Neilson, Daniel J. Murphy, David Y. Lewis, Helen L. Reeves, John Le Quesne, Derek A. Mann, Leo M. Carlin, Karen Blyth, Josep M. Llovet, Markus H. Heim, Owen J. Sansom, Crispin Miller, Thomas G. Bird (2025). Human-correlated genetic models identify precision therapy for liver cancer. Nature, DOI: 10.1038/s41586-025-08585-z.
Article145 days agoCXCR2 inhibition enables NASH-HCC immunotherapy
Jack Leslie, John B. G. Mackey, Thomas Jamieson, Erik Ramón-Gil, Thomas M. Drake, Frédéric Fercoq, William Clark, Kathryn Gilroy, Ann Hedley, Colin Nixon, Saimir Luli, Maja Laszczewska, Roser Pinyol, Roger Esteban-Fabró, Catherine E. Willoughby, Philipp K. Haber, Carmen Andreu-Oller, Mohammad Rahbari, Chaofan Fan, Dominik Pfister, Shreya Raman, Niall Wilson, Miryam Müller, Amy Collins, Daniel Geh, Andrew Fuller, David McDonald, Gillian Hulme, Andrew Filby, Xabier Cortés-Lavaud, Noha-Ehssan Mohamed, Catriona A. Ford, Ximena L. Raffo Iraolagoitia, Amanda J. McFarlane, Misiti McCain, Rachel A. Ridgway, Edward W. Roberts, Simon T. Barry, Gerard J. Graham, Mathias Heikenwälder, Helen L. Reeves, Josep M. Llovet, Leo M. Carlin, Thomas G. Bird, Owen J. Sansom, Derek A. Mann (2022). CXCR2 inhibition enables NASH-HCC immunotherapy. bioRxiv (Cold Spring Harbor Laboratory), DOI: 10.1101/2022.02.24.481779.
Preprint145 days ago